Motor symptoms in nonparaneoplastic CNS disorders associated with neural antibodies.
Autoimmune encephalitis
Autoimmunity
Motor symptoms
Movement disorders
Neuronal antibodies
Journal
Handbook of clinical neurology
ISSN: 0072-9752
Titre abrégé: Handb Clin Neurol
Pays: Netherlands
ID NLM: 0166161
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Motor symptoms are common, and sometimes predominant, in almost all nonparaneoplastic CNS disorders associated with neural antibodies. These CNS disorders can be classified into five groups: (1) Autoimmune encephalitis with antibodies against synaptic receptors, (2) cerebellar ataxias associated with neuronal antibodies that mostly target intracellular antigens. (3) Stiff-person syndrome and progressive encephalomyelitis with rigidity and myoclonus which have antibodies against glutamic acid decarboxylase and glycine receptor, respectively. Both diseases have in common the presence of predominant muscle stiffness and rigidity. (4) Three diseases associated with glial antibodies. Two present motor symptoms mainly due to the involvement of the spinal cord: neuromyelitis optica spectrum disorders with aquaporin-4 antibodies and myelin oligodendrocyte glycoprotein antibody-associated disease. The third disorder is the meningoencephalitis associated with glial fibrillar acidic protein antibodies which frequently also presents a myelopathy. (5) Two antibody-related diseases which are characterized by prominent sleep dysfunction: anti-IgLON5 disease, a disorder that frequently presents a variety of movement disorders, and Morvan syndrome associated with contactin-associated protein-like 2 antibodies and clinical manifestations of peripheral nerve hyperexcitability. In this chapter, we describe the main clinical features of these five groups with particular emphasis on the presence, frequency, and types of motor symptoms.
Identifiants
pubmed: 37620074
pii: B978-0-323-98817-9.00004-1
doi: 10.1016/B978-0-323-98817-9.00004-1
pii:
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-294Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Author disclosures Dr. Graus holds a patent licensed to Euroimmun for the use of IgLON5 in an autoantibody test, for which he receives royalties. He receives honoraria for consultancy work for Lundbeck and from MedLink Neurology for his role as associate editor. Dr. Gaig has received honoraria for consultancy for Bioprojet and Symposium honoraria for Bioprojet, UCB, and Jazz Pharma.